Author

Pablo Sánchez Vela

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-9286-8290Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Ross L. LevineiD· 3 shared Richard P. KocheiD· 2 shared Aaron James StonestromiD· 1 shared Ahmet ZehiriD· 1 shared Aishwarya KrishnaniD· 1 shared Alan H. ShihiD· 1 shared Alberto Bueno Costa· 1 shared Alexander G. Goglia· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Ross L. LevineORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Short-read whole-genome sequencing identifies the Tg(Tal1-cre/ERT)42-056Jrg transgene insertion site on mouse chromosome 4

Xiaodi Wu, Maya C. Bagish, Pablo Sánchez Vela, Alexander G. Goglia, Ross L. Levine

bioRxiv · Nov 5, 2026 · PreprintGenetics

TET2 and TP53 Mutations Cooperatively Modulate the Response to Inflammation to Promote Leukemic Transformation

Pablo Sánchez Vela, Brianna Kelly, Claudia Brady, Jonathan Foox, Jacob Lowell Glass, Richard P. Koche, Matthew G. Wereski, Isabelle Sara Csete, Sebastian El Ghaity-Beckley, Bridget Kelly Marcellino, Ross L. Levine, Alan H. Shih

This study shows that TET2 and TP53 mutations work together to promote leukemic transformation by altering inflammatory responses and chemotherapy tolerance in hematopoietic stem cells.

bioRxiv · Jan 20, 2026 · PreprintCancer Biology

Targetable Treatment Resistance in Thyroid Cancer with Clonal Hematopoiesis

Vera Tiedje, Pablo Sánchez Vela, Julie L. Yang, Brian R. Untch, Laura Boucai, Aaron James Stonestrom, Alberto Bueno Costa, Sebastià Franch‐Expósito, Avi Srivastava, Marina Kerpelev, Jillian Greenberg, Mathew Wereski, Amanda R. Kulick, Kevin Chen, Tianyue Qin, , Ross L. Levine

This study identifies TET2-mutant clonal hematopoiesis in thyroid cancer microenvironments and shows that TGFβ signaling from these macrophages mediates resistance to BRAF/MEK inhibition, with TGFβ inhibition restoring sensitivity.

bioRxiv · Oct 10, 2024 · PreprintCancer Biology